Literature DB >> 22364559

Obesity-dependent metabolic signatures associated with nonalcoholic fatty liver disease progression.

J Barr1, J Caballería, I Martínez-Arranz, A Domínguez-Díez, C Alonso, J Muntané, M Pérez-Cormenzana, C García-Monzón, R Mayo, A Martín-Duce, M Romero-Gómez, O Lo Iacono, J Tordjman, R J Andrade, M Pérez-Carreras, Y Le Marchand-Brustel, A Tran, C Fernández-Escalante, E Arévalo, M García-Unzueta, K Clement, J Crespo, P Gual, M Gómez-Fleitas, M L Martínez-Chantar, A Castro, S C Lu, M Vázquez-Chantada, J M Mato.   

Abstract

Our understanding of the mechanisms by which nonalcoholic fatty liver disease (NAFLD) progresses from simple steatosis to steatohepatitis (NASH) is still very limited. Despite the growing number of studies linking the disease with altered serum metabolite levels, an obstacle to the development of metabolome-based NAFLD predictors has been the lack of large cohort data from biopsy-proven patients matched for key metabolic features such as obesity. We studied 467 biopsied individuals with normal liver histology (n=90) or diagnosed with NAFLD (steatosis, n=246; NASH, n=131), randomly divided into estimation (80% of all patients) and validation (20% of all patients) groups. Qualitative determinations of 540 serum metabolite variables were performed using ultraperformance liquid chromatography coupled to mass spectrometry (UPLC-MS). The metabolic profile was dependent on patient body-mass index (BMI), suggesting that the NAFLD pathogenesis mechanism may be quite different depending on an individual's level of obesity. A BMI-stratified multivariate model based on the NAFLD serum metabolic profile was used to separate patients with and without NASH. The area under the receiver operating characteristic curve was 0.87 in the estimation and 0.85 in the validation group. The cutoff (0.54) corresponding to maximum average diagnostic accuracy (0.82) predicted NASH with a sensitivity of 0.71 and a specificity of 0.92 (negative/positive predictive values=0.82/0.84). The present data, indicating that a BMI-dependent serum metabolic profile may be able to reliably distinguish NASH from steatosis patients, have significant implications for the development of NASH biomarkers and potential novel targets for therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22364559      PMCID: PMC3321123          DOI: 10.1021/pr201223p

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  41 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

Review 2.  NASH--hepatic metabolism and not simply the metabolic syndrome.

Authors:  Richard M Green
Journal:  Hepatology       Date:  2003-07       Impact factor: 17.425

3.  Where are we in the search for noninvasive nonalcoholic steatohepatitis biomarkers?

Authors:  José M Mato; Shelly C Lu
Journal:  Hepatology       Date:  2011-10       Impact factor: 17.425

4.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.

Authors:  A J Sanyal; C Campbell-Sargent; F Mirshahi; W B Rizzo; M J Contos; R K Sterling; V A Luketic; M L Shiffman; J N Clore
Journal:  Gastroenterology       Date:  2001-04       Impact factor: 22.682

Review 5.  Adipose tissue as a buffer for daily lipid flux.

Authors:  K N Frayn
Journal:  Diabetologia       Date:  2002-07-24       Impact factor: 10.122

6.  Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism.

Authors:  C Y Fan; J Pan; N Usuda; A V Yeldandi; M S Rao; J K Reddy
Journal:  J Biol Chem       Date:  1998-06-19       Impact factor: 5.157

Review 7.  Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome.

Authors:  Roger H Unger
Journal:  Endocrinology       Date:  2003-09-04       Impact factor: 4.736

8.  The measurement of carnitine and acyl-carnitines: application to the investigation of patients with suspected inherited disorders of mitochondrial fatty acid oxidation.

Authors:  A K Bhuiyan; S Jackson; D M Turnbull; A Aynsley-Green; J V Leonard; K Bartlett
Journal:  Clin Chim Acta       Date:  1992-05-15       Impact factor: 3.786

9.  Hepatic secretion of VLDL fatty acids during stimulated lipogenesis in men.

Authors:  A Aarsland; R R Wolfe
Journal:  J Lipid Res       Date:  1998-06       Impact factor: 5.922

10.  Disappearance of plasmalogens from membranes of animal cells subjected to photosensitized oxidation.

Authors:  O H Morand; R A Zoeller; C R Raetz
Journal:  J Biol Chem       Date:  1988-08-15       Impact factor: 5.157

View more
  73 in total

Review 1.  Nonalcoholic fatty liver disease: update on pathogenesis, diagnosis, treatment and the role of S-adenosylmethionine.

Authors:  Mazen Noureddin; José M Mato; Shelly C Lu
Journal:  Exp Biol Med (Maywood)       Date:  2015-04-13

2.  Association Between Circulating Lipids and Future Weight Gain in Individuals With an At-Risk Mental State and in First-Episode Psychosis.

Authors:  Santosh Lamichhane; Alex M Dickens; Partho Sen; Heikki Laurikainen; Faith Borgan; Jaana Suvisaari; Tuulia Hyötyläinen; Oliver Howes; Jarmo Hietala; Matej Orešič
Journal:  Schizophr Bull       Date:  2021-01-23       Impact factor: 9.306

3.  Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease.

Authors:  Cyrielle Caussy; Veeral H Ajmera; Puneet Puri; Cynthia Li-Shin Hsu; Shirin Bassirian; Mania Mgdsyan; Seema Singh; Claire Faulkner; Mark A Valasek; Emily Rizo; Lisa Richards; David A Brenner; Claude B Sirlin; Arun J Sanyal; Rohit Loomba
Journal:  Gut       Date:  2018-12-19       Impact factor: 23.059

4.  Serum metabolomic profiling highlights pathways associated with liver fat content in a general population sample.

Authors:  M Koch; S Freitag-Wolf; S Schlesinger; J Borggrefe; J R Hov; M K Jensen; J Pick; M R P Markus; T Höpfner; G Jacobs; S Siegert; A Artati; G Kastenmüller; W Römisch-Margl; J Adamski; T Illig; M Nothnagel; T H Karlsen; S Schreiber; A Franke; M Krawczak; U Nöthlings; W Lieb
Journal:  Eur J Clin Nutr       Date:  2017-04-05       Impact factor: 4.016

Review 5.  Systems biology for hepatologists.

Authors:  José M Mato; M Luz Martínez-Chantar; Shelly C Lu
Journal:  Hepatology       Date:  2014-06-18       Impact factor: 17.425

6.  Methionine and S-adenosylmethionine levels are critical regulators of PP2A activity modulating lipophagy during steatosis.

Authors:  Imanol Zubiete-Franco; Juan Luis García-Rodríguez; Maite Martínez-Uña; Nuria Martínez-Lopez; Ashwin Woodhoo; Virginia Gutiérrez-De Juan; Naiara Beraza; Sergio Lage-Medina; Fernando Andrade; Marta Llarena Fernandez; Luis Aldámiz-Echevarría; David Fernández-Ramos; Juan Manuel Falcon-Perez; Fernando Lopitz-Otsoa; Pablo Fernandez-Tussy; Lucía Barbier-Torres; Zigmund Luka; Conrad Wagner; Carmelo García-Monzón; Shelly C Lu; Patricia Aspichueta; José María Mato; María Luz Martínez-Chantar; Marta Varela-Rey
Journal:  J Hepatol       Date:  2015-09-21       Impact factor: 25.083

7.  Metabolomic Identification of Subtypes of Nonalcoholic Steatohepatitis.

Authors:  Cristina Alonso; David Fernández-Ramos; Marta Varela-Rey; Ibon Martínez-Arranz; Nicolás Navasa; Sebastiaan M Van Liempd; José L Lavín Trueba; Rebeca Mayo; Concetta P Ilisso; Virginia G de Juan; Marta Iruarrizaga-Lejarreta; Laura delaCruz-Villar; Itziar Mincholé; Aaron Robinson; Javier Crespo; Antonio Martín-Duce; Manuel Romero-Gómez; Holger Sann; Julian Platon; Jennifer Van Eyk; Patricia Aspichueta; Mazen Noureddin; Juan M Falcón-Pérez; Juan Anguita; Ana M Aransay; María Luz Martínez-Chantar; Shelly C Lu; José M Mato
Journal:  Gastroenterology       Date:  2017-01-26       Impact factor: 22.682

8.  Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.

Authors:  Zobair M Younossi; Rohit Loomba; Quentin M Anstee; Mary E Rinella; Elisabetta Bugianesi; Giulio Marchesini; Brent A Neuschwander-Tetri; Lawrence Serfaty; Francesco Negro; Stephen H Caldwell; Vlad Ratziu; Kathleen E Corey; Scott L Friedman; Manal F Abdelmalek; Stephen A Harrison; Arun J Sanyal; Joel E Lavine; Philippe Mathurin; Michael R Charlton; Zachary D Goodman; Naga P Chalasani; Kris V Kowdley; Jacob George; Keith Lindor
Journal:  Hepatology       Date:  2018-07       Impact factor: 17.425

9.  Synthesis and anti-obesity effects in vivo of Crotadihydrofuran C as a novel PPARγ antagonist from Crotalaria albida.

Authors:  Qin-Hu Sun; Yu Zhang; Gui-Xin Chou
Journal:  Sci Rep       Date:  2017-04-24       Impact factor: 4.379

10.  A Pilot Study of Serum Sphingomyelin Dynamics in Subjects with Severe Obesity and Non-alcoholic Steatohepatitis after Sleeve Gastrectomy.

Authors:  Bruno Ramos-Molina; Daniel Castellano-Castillo; Oscar Pastor; Luis Ocaña-Wilhelmi; Diego Fernández-García; Manuel Romero-Gómez; Fernando Cardona; Francisco J Tinahones
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.